

PROGRAMME OF LIVE SESSIONS: CEST timing

The programme below will take place live. This time schedule corresponds to **CEST timing**. [Click here](#) to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Table, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting!



Conference

**8th Translational Research E-Conference
MYELODYSPLASTIC SYNDROMES**

April 7-10, 2022

Chairpersons: Pierre Fenaux (Paris), Uwe Platzbecker (Leipzig), Mikkael Sekeres (Miami)

Thursday, April 7th, 2022

13:30–13:40 Welcome: Pierre Fenaux (Paris), Uwe Platzbecker (Leipzig), Mikkael Sekeres (Miami)

SESSION I – Disease biology: the genomics and its consequences in myelodysplastic syndromes

Chair: Pierre Fenaux (Paris)

13:40-13:45	Introduction	Pierre Fenaux (Paris)
13:45-14:00	CHIP: Clonal hematopoiesis of not-so-indeterminate potential	Klaus Metzeler (Leipzig)
14:00-14:15	Clonal cytopenia of undetermined significance	Luca Malcovati (Pavia)
14:15-14:30	Epigenetic deregulation in MDS	Maria Figueroa (Miami)
14:30-14:45	sAML vs. de novo AML	Felicita Thol (Hannover)
14:45-14:52	<u>Brief oral communication</u> Transient Monosomy 7 in SAMD9/9L syndromes: is it safe to watch and wait?	Miriam Erlacher (Freiburg)
14:52-15:25	<i>Panel discussion</i>	

15:25-15:35 Coffee Break

SESSION II – Disease biology:

Immune and microenvironment alterations and its implications in myelodysplastic syndromes

Chair: Mikkael Sekeres (Miami)

15:35-15:40	Introduction	Mikkael Sekeres (Miami)
15:40-15:55	The immunome	Shahram Kordasti (London)
15:55-16:10	Impact of the microbiome on hematopoiesis	Katherine King (Houston)
16:10-16:25	The niche	Marc Raaijmakers (Rotterdam)
16:25-16:40	The case of iron	Valeria Santini (Florence)
16:40-16:47	<u>Brief oral communication</u> Interplay between inflammation and epigenetics in tumor reprogramming of mesenchymal stromal cells (MSCs) in myelodysplastic syndromes (MDS)	Cesarina Giallongo (Catania)
16:47-17:20	<i>Panel discussion</i>	

17:40-18:40 Mentored poster walk

- **Biology poster walk leaders** : Michaela Fontenay (Paris) & Jaroslaw Maciejewski (Cleveland)
- **Clinical poster walk leaders** : Thomas Cluzeau (Nice) & Anne Sophie Kubasch (Leipzig)

Friday, April 8th, 2022

13:00-14:00 SATELLITE SYMPOSIUM:
From laboratory to clinic:
Targeting the immune system to obtain durable responses in Higher Risk MDS
Chair: Pierre Fenaux (Paris)
Speakers: Valeria Santini (Florence) & Marc Raaijmakers (Rotterdam)

This educational symposium is organized and funded by Novartis

SESSION III – The future of myelodysplastic syndromes research

Chair: Michaela Fontenay (Paris)

14:10-14:15	Introduction	Michaela Fontenay (Paris)
14:15-14:30	Single and Stem Cell Heterogeneity in MDS	Ulrich Steidl (New York)
14:30-14:45	Investigating the cross-talk between MDS and the BM niche using a humanised BM niche mode	Dominique Bonnet (London)
14:45-15:00	Artificial intelligence for treatment and prognosis	Anne Sophie Kubasch (Leipzig)

15:00-15:15 PDX vs 3D-HOMEs Daniel Nowak (Mannheim)

15:15-15:22 Brief oral communication
Small molecule inhibitor of Lysyl Oxidases synergizes
with 5-Azacytidine to restore erythropoiesis in myeloid neoplasms Daniel Nowak (Mannheim)

15:22-15:55 *Panel discussion*

15:55-16:05 Coffee Break

**SESSION IV – When is myelodysplastic syndromes really myelodysplastic syndromes,
and when is it really bad myelodysplastic syndromes? Diagnosis and prognosis**

Chair: Valeria Santini (Florence)

16:05-16:10 Introduction Valeria Santini (Florence)

16:10-16:25 The basics are enough: morphology, flow cytometry,
and cytogenetics to diagnose MDS Aristoteles Giagounidis (Düsseldorf)

16:25-16:40 The basics are not enough: how molecular genetics
make the difference of MDS Torsten Haferlach (Munich)

16:40-16:55 The best clinical prognostic system for MDS is... Rami Komrokji (Tampa)

16:55-17:10 The best soup has many ingredients: prognosis in
MDS combining clinical and biologic information Jaroslaw Maciejewski (Cleveland)

17:10-17:17 Brief oral communication
Treatment patterns and overall survival in patients with
intermediate-risk myelodysplastic syndrome (MDS):
a retrospective analysis from the
Grupo Español De Síndromes Mielodisplásicos (GESMD) Spanish MDS registry Maria Diez Campelo (Salamanca)

17:17-17:50 *Panel discussion*

18:00-19:00 3 Simultaneous meet the expert sessions

1. Practical management of higher risk myelodysplastic syndromes Mikkael Sekeres (Miami) & Lionel Adès (Paris)
2. Practical management of anemia of lower risk myelodysplastic syndromes Pierre Fenaux (Paris) & Valeria Santini (Florence)
3. Practical management of chronic myelomonocytic leukemia Raphael Itzykson (Paris) & Eric Solary (Paris)

13:00-14:00 SATELLITE SYMPOSIUM:

The Impact of Mutational Profiling on the Lower-risk MDS Treatment Paradigm

Chair: Valeria Santini (Florence)

Speakers: Marc Raaijmakers (Rotterdam) & Rami S. Komrokji (Tampa)

This educational symposium is organized and funded by Bristol Myers Squibb

SESSION V – Special groups in myelodysplastic syndromes

Chair: Pierre Fenaux (Paris)

14:10-14:15	Introduction	Pierre Fenaux (Paris)
14:15-14:30	Spliceosome mutations: the voyage out	Michaela Fontenay (Paris)
14:30-14:45	Why and how should we target mature cells of the clone in chronic myelomonocytic leukemia?	Eric Solary (Paris)
14:45-15:00	Can quality of life be used to guide care for patients with MDS?	Gregory A. Abel (Boston)
15:00-15:15	How to best define del (5q)	Maria Diez Campelo (Salamanca)
15:15-15:22	<u>Brief oral communication</u> Vitamin B5 and Succinyl-CoA improve ineffective erythropoiesis in SF3B1 mutated myelodysplasia	Celine Philippe (London)
15:22-15:55	<i>Panel discussion</i>	

15:55-16:05 Coffee Break

SESSION VI – Treatment of myelodysplastic syndromes

Chair: Eva Hellström-Lindberg (Stockholm)

16:05-16:10	Introduction	Eva Hellström-Lindberg (Stockholm)
16:10-16:25	ESA and other growth factors	Eva Hellström-Lindberg (Stockholm)
16:25-16:40	HMAs: when and how	Mikael Sekeres (Miami)
16:40-16:55	Allo transplantation: when and how?	Marie Robin (Paris)
16:55-17:10	Current treatment guidelines for CMML and rare subtypes	Raphael Itzykson (Paris)
17:10-17:25	Overview of novel therapeutics in MDS: lessons from the lab	Valeria Santini (Florence)
17:25-17:32	<u>Brief oral communication</u> PARP inhibitors promote reversible clonal haematopoiesis:	Ellen Nuttall Musson (London)

real world data on clone dynamics and regression

17:32-18:05 *Panel discussion*

18:15-19:15 2 Simultaneous meet the expert sessions (biological)

1. How to best use NGS analysis in MDS : diagnosis, prognosis, Mrd
2. The IPSS-M in practice

Jaroslav Maciejewski (Cleveland) &
Torsten Haferlach (Munich)
Elsa Bernard (New York) &
Rami Komrokji (Tampa)

Sunday, April 10th, 2022

SESSION VII – Current progress in the treatment of myelodysplastic syndromes

Chair: Lionel Adès (Paris)

11:00-11:05	Introduction	Lionel Adès (Paris)
11:05-11:20	Strategies to improve HMA based therapy	Pierre Fenaux (Paris)
11:20-11:35	Higher risk MDS: lessons from elderly AML	Lionel Adès (Paris)
11:35-11:50	A renewed role for intensive chemotherapy ?	Thomas Cluzeau (Nice)
11:50-12:05	Novel strategies to treat cytopenia in low risk MDS	Uwe Platzbecker (Leipzig)
12:05-12:12	<u>Brief oral communication</u> CPX 351 as first line treatment in higher risk MDS. a Phase II trial by the GFM	Pierre Peterlin (Nantes)
12:12-12:45	<i>Panel discussion</i>	
12:45-13:05	Keynote lecture: Routine integration of molecular data in the prognostic stratification: the IPSS molecular	Elsa Bernard (New York)
13:05 -13:10	<i>Discussion</i>	
13:10 -13:40	Lunch	

SESSION VIII– Clinical trials in Europe and USA myelodysplastic syndromes consortium

Chair: Raphael Itzykson (Paris)

13:40 -13:45	Introduction	Raphael Itzykson (Paris)
13:45 -14:30	Current MDS/CMML clinical trials in Europe: Ongoing MDS Studies in Italy GESMD clinical trials and projects GFM clinical trials in 2022 Clinical trials - German MDS study group / EMSCO	Valeria Santini (Florence) Maria Diez Campelo (Salamanca) Pierre Fenaux (Paris) Anne Sophie Kubasch (Leipzig) & Silke Gloaguen (Leipzig)

14:30 -15:30 *Panel discussion (including US MDS consortium by Mikkael Sekeres [Miami])*

SESSION IX – Late-breaking top news

Chair: Maria Diez Campelo (Salamanca)

15:30-15:35	Introduction	Maria Diez Campelo (Salamanca)
15:35-15:50	Rethinking clinical trial endpoints in myelodysplastic syndromes	Mikkael Sekeres (Miami)
15:50-16:05	An interim report on new international MDS guidelines	Eva Hellström-Lindberg (Stockholm)
16:05-16:20	APR 246, Magorlimab and other potential drugs active in MDS/AML with TP53 mutation	Thomas Cluzeau (Nice)
16:20-16:35	New EU clinical trials regulation	Joanna Wilińska-Maćkowiak (Bremen)
16:35-17:05	<i>Panel discussion</i>	
17:05-17:15	<i>Closing remarks</i>	